ZIOPHARM Oncology, Inc. (ZIOP) Financial Analysis & Valuation | Quarter Chart
ZIOPHARM Oncology, Inc. (ZIOP)
ZIOPPrice: $0.87
Fair Value: 🔒
🔒score
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engin... more
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiri... more
Description
Shares
| Market Cap | $208.12M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Laurence Cooper |
| IPO Date | 2004-08-20 | CAGR | — |
| Employees | 103 | Website | ziopharm.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ZIOP chart loading...
Fundamentals
Technicals
| Enterprise Value | $1.45B | P/E Ratio | -2.07 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 902.58 | P/B Ratio | 1.13 |
| P/CF Ratio | 0.12 | P/FCF Ratio | 0.15 |
| EPS | $-0.42 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | 1.67% |
| Operating Margin | -672.67% | Profit Margin | -665.5% |
| ROE | -1.68% | ROA | -0.84% |
| ROCE | -1.1% | Current Ratio | 3.48 |
| Quick Ratio | 3.48 | Cash Ratio | 2.68 |
| Debt/Equity | — | Interest Coverage | — |
| Altman Z Score | -129.85 | Piotroski Score | 5 |